Kodiak Sciences Inc (KOD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kodiak Sciences Inc (KOD) has a cash flow conversion efficiency ratio of -0.357x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.01 Million) by net assets ($112.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KOD equity financing ratio to measure how much of total assets are equity-financed.
Kodiak Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Kodiak Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore KOD long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Kodiak Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kodiak Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ANSELL (UNSP.ADRS)/4
F:PD1
|
N/A |
|
Unibel S.A
PA:UNBL
|
0.077x |
|
Espressif Systems Shanghai Co Ltd
SHG:688018
|
0.046x |
|
Tongding Interconnection Information
SHE:002491
|
-0.002x |
|
Lennar Corporation
NYSE:LEN-B
|
-0.015x |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
-0.009x |
|
SolarEdge Technologies Inc
NASDAQ:SEDG
|
0.059x |
|
Keboda Technology Co Ltd
SHG:603786
|
0.045x |
Annual Cash Flow Conversion Efficiency for Kodiak Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kodiak Sciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see KOD market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $157.38 Million | $-136.01 Million | -0.864x | -10.70% |
| 2024-12-31 | $150.29 Million | $-117.32 Million | -0.781x | -34.56% |
| 2023-12-31 | $265.78 Million | $-154.18 Million | -0.580x | -22.56% |
| 2022-12-31 | $436.17 Million | $-206.46 Million | -0.473x | -72.26% |
| 2021-12-31 | $663.32 Million | $-182.27 Million | -0.275x | -183.50% |
| 2020-12-31 | $860.75 Million | $-83.43 Million | -0.097x | +14.49% |
| 2019-12-31 | $345.36 Million | $-39.15 Million | -0.113x | +66.10% |
| 2018-12-31 | $86.83 Million | $-29.03 Million | -0.334x | -230.17% |
| 2017-12-31 | $-68.74 Million | $-17.66 Million | 0.257x | -34.24% |
| 2016-12-31 | $-41.08 Million | $-16.05 Million | 0.391x | -- |
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more